Helen Parker

Helen Parker is a Researcher in the Division of Immunology, Immunity to Infection and Respiratory Medicine, focusing on lysosomal storage diseases, stem cell therapies, and neurodegenerative mechanisms. Her work addresses mucopolysaccharidosis (MPS IIIA) and systemic inflammation's impact on neurological disorders.

Research interests include developing novel mouse models for MPS IIIA, investigating meningeal immune responses, and engineering nanotechnology-based treatments for glioblastoma. Her interdisciplinary studies bridge immunology, neuroscience, and pharmacology to advance therapeutic strategies.

Recent publications highlight collaborations in creating immunodeficient mouse models for stem cell therapies, systemic immune challenges in neurodegeneration, and graphene oxide nanosheets for cancer microenvironment modulation. These studies underscore her role in translating preclinical research into potential clinical applications.

No scientific awards are explicitly mentioned, but her work contributes to UN Sustainable Development Goals related to health and innovation.

Her research involves close collaboration with teams exploring genetic disorders, immunology, and nanomedicine, though specific grants or labs are not detailed in the text.